SCHEMBL2384143

SCHEMBL2384143

CC1CN(c2nsnc2OCc2ccncc2)CC(C)N1C(=O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 5/20 0.52
▸ KDR P35968 4/20 0.40
▸ FLT1 P17948 3/20 0.40
▸ F10 P00742 1/20 0.40
▸ EPHB4 P54760 1/20 0.39
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CACNA1G O43497 2/20 0.37
▸ CACNA1H O95180 2/20 0.37
▸ CACNA1I Q9P0X4 2/20 0.37
▸ CHRM4 P08173 1/20 0.36
▸ TACR1 P25103 2/20 0.36
▸ LIMK2 P53671 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TRPA1 O75762 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382825 0.94 TRPV1 (0.51) TRPV1KDRFLT1F10EPHB4
SCHEMBL2382762 0.90 TRPV1 (0.55) TRPV1KDRFLT1F10EPHB4
SCHEMBL2384981 0.90 TRPV1 (0.54) TRPV1F10CHRM2CHRM1CHRM4
SCHEMBL2385509 0.90 TRPV1 (0.54) TRPV1F10CHRM2CHRM1CHRM4
SCHEMBL2383659 0.90 TRPV1 (0.54) TRPV1F10CHRM2CHRM1CHRM4
SCHEMBL2382772 0.84 TRPV1 (0.49) TRPV1HSD17B10
SCHEMBL2385012 0.84 TRPV1 (0.55) TRPV1KDRFLT1F10EPHB4
SCHEMBL2383664 0.83 TRPV1 (0.53) TRPV1KDRFLT1F10EPHB4
SCHEMBL2384709 0.83 TRPV1 (0.53) TRPV1KDRFLT1F10EPHB4
SCHEMBL12250883 0.83 TRPV1 (0.53) TRPV1KDRFLT1F10EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR TRPV1 4108/4885KDR 3/4885FLT1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback